Curebase Partners with Redenlab to Expand Data Capture Capabilities in Pharma Trials

Curebase, a company dedicated to democratizing clinical trials through a decentralized model is announcing its partnership with Redenlab, a global leader for speech testing in industry-run clinical trials.

Speech can be a sensitive marker for specific neuro conditions that is often a crucial aspect of patient monitoring for pharmaceutical trials in the neuro space. Redenlab, a neuroscience technology company, uses speech and language biometrics to enhance decision-making in clinical trials. The Redenlab user-friendly digital speech platform provides flexible, objective measurement and analysis of communication ability that can evaluate the efficacy of pharmaceutical treatments, as tools for monitoring patient health in medical clinics, and in cutting-edge academic research.

Recommended AI: “Bitcoin Has No Intrinsic Value”. Then What Gives Bitcoin Value?

Curebase can integrate with Redenlab’s platform with built-in AWS and HIPPA compliance, as a way to add speech analytics to pharmaceutical studies where necessary. This analytical component will not only give researchers a more comprehensive monitoring approach in trials but will also add to patient safety and well-being during trials.

“Our cognitive-linguistic tests are valid, quick, and reliable, with demonstrated sensitivity to subtle disease or treatment-induced change,” says Dr. Adam Vogel, CEO of Redenlab. “We service in-clinic, in-home or virtual trials with speech software and hardware solutions capable of meeting regulatory requirements for security and integrity of data in clinical trials.”

Recommended AI: Top 10 Countries and Cities by Number of CCTV Cameras

Curebase can utilize these capabilities where applicable in pharma and neuro trials to collect crucial metrics in a decentralized study model.

“Data quality is a huge component to DCTs, being able to offer specific analytics to our research studies levels up our data collection capabilities in our trials,” says Tom Lemberg, founder & CEO of Curebase. “By incorporating Redenlab’s technology into pharma studies where necessary, we are able to produce quality data points where they matter.”

Partnerships like these enable sponsors to collect comprehensive and relevant data metrics in accordance with regulatory requirements for necessary trials.

Recommended AI: How is Artificial Intelligence (AI) Changing the Future of Architecture?

[To share your insights with us, please write to sghosh@martechseries.com]